New Jersey opens more cannabis dispensaries to regulate psychotropic hemp products

To better control products containing cannabinoids derived from hemp such as delta-8-THC, New Jersey has adopted a new approach: the state facilitates access for certain medical cannabis dispensaries to the adult market.

Medical dispensaries enter the adult market

At the heart of this reform is New Jersey Assembly Bill A5051, signed by Governor Mikie Sherrill on May 29, which changes the way certain medical cannabis operators can obtain a recreational retail license.

Under the new law, medical dispensaries that had been licensed by municipalities prior to the legalization of recreational cannabis will no longer need to apply for additional municipal authorization to add recreational sales. Instead, their existing approval as a cannabis business will be considered sufficient to obtain a class 5 cannabis retailer license.

This measure concerns a limited number of operators located in municipalities that currently prohibit the sale of recreational cannabis.

Supporters of the bill argue that these businesses have already been vetted at the local level and should not be required to undergo a second licensing process. They argue that removing this administrative hurdle will allow established operators to participate more fully in New Jersey's growing legal cannabis market.

This change also means that the New Jersey Cannabis Regulatory Commission (CRC) will no longer require proof of municipal authorization when reviewing eligible applications from existing medical dispensaries.

Stricter regulation of psychoactive hemp products

While the change in licenses has attracted a lot of attention, the main aim of the bill is actually to regulate psychoactive products derived from hemp.

Legislation imposes strict limits on cannabinoid products derived from hemp, targeting the following compounds in recent years in convenience stores, tobacconists and online sales platforms. Products containing synthetic cannabinoids or cannabinoids obtained through chemical conversion processes are particularly targeted.

The law also tightens restrictions on the online sale of psychoactive hemp products, and provides for severe penalties for non-compliant products.

At the same time, legislators decided to postpone the full implementation of certain restrictions on hemp until November 13, 2026. The postponement is intended to give regulators time to align state rules with expected federal guidelines for hemp-derived cannabinoids.

This reform illustrates a growing trend among US states: rather than allowing hemp-based psychotropic products to remain largely outside the regulated cannabis system, legislators are increasingly directing consumers towards licensed cannabis distribution channels.

Since the launch of recreational cannabis sales in 2022, the State experienced rapid growth in the cannabis sector. According to CRC data, over 560 cannabis businesses have already been approved or licensed.